Project Grant R01CA303124
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $433,157 to the Northshore University Healthsystem Research Institute to investigate the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The primary objectives are to define the mechanisms regulating the immuno-metabolic axis in adipose tissue macrophages and tumor-associated macrophages, and determine whether a metabolically-activated macrophage...
- The University of South Alabama was awarded a $369,868 Project Grant from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) on July 7, 2025. The grant supports research to investigate the functional role of the intercellular transfer of mitochondria between nerves and cancer cells, particularly in the context of triple-negative breast cancer metastasis. The key objectives of the 5-year project are to: 1) Determine the contribution of nerve-to-cancer mitochondrial transfer in...
- This federal Project Grant award, valued at $641,936 and funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop novel strategies to program tumor-associated neutrophils as antitumor effector cells for the treatment of glioblastoma (GBM), the most aggressive type of brain cancer. The project will leverage synthetic biology, machine learning, and next-generation sequencing to interrogate tumor-associated neutrophils and develop methods to reprogram...
- This $642,755 Project Grant award from the National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), supports research by The Institute for Cancer Research (ICR) to investigate the role of the protein Anoctamin 6 (ANO6) in disrupting the trogocytosis process that enables cancer-associated fibroblasts to transfer lipids to pancreatic ductal adenocarcinoma (PDAC) tumor cells. The research aims to elucidate how ANO6 activity is regulated in the...
- This federal Project Grant award of $513,127 from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) supports research by The University of Texas MD Anderson Cancer Center to investigate the role of cancer pain-associated neuronal activity in driving malignancies. The researchers aim to uncover how malignant peripheral nerve sheath tumor (MPNST) cells activate sensory neurons to promote cancer pain, and determine the mechanisms by which pain-associated...
- This $667,118 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "Identifying and Disabling New Pathways for Macromolecular Recycling in Pancreatic Cancer". The project will focus on studying the role of key lysosomal factors, including PLBD1 and LGMN, that are essential for the survival and growth of pancreatic ductal...
- This $370,575 project grant from the National Institutes of Health National Cancer Institute Cancer Biology Research program (CFDA 93.396) will fund research at the University of Cincinnati investigating the molecular mechanisms of growth in pancreatic cancer with GNAS mutations. The grant supports studies from August 1, 2022 to July 31, 2027 to further the understanding of the oncogenic functions of mutant GNAS and its downstream signaling pathways. Specifically, the research will illuminate...
- This $214,583 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Tulane University will fund research to evaluate the role of the extracellular matrix in triple-negative breast cancer (TNBC) progression and treatment response, with a focus on African American patient populations. The research aims to provide insights on key extracellular matrix proteins that regulate TNBC tumorigenesis, metastasis, and response to therapy, using 3D in...
- The National Cancer Institute awarded a $134,274 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Tufts University School of Medicine in Boston, MA. The goal of this 3.5-year project, starting December 1, 2024 and ending June 30, 2028, is to investigate the role of the TRPV1 ion channel in driving increased sensory nerve innervation within triple-negative breast cancer (TNBC) tumors. The research aims to uncover the mechanism by which TNBC cells stimulate...
- The National Cancer Institute awarded a $148,500 Project Grant under the Cancer Biology Research Program (CFDA 93.396) to the University of North Texas to evaluate the role of extracellular vesicles in modulating the tumor microenvironment, with a focus on their impact on T cell infiltration and suppression in non-small cell lung cancer (NSCLC) and prostate cancer. The project aims to identify specific subpopulations of tumor-derived extracellular vesicles, such as TGN46+ vesicles, that...
This federal Project Grant award of $1,575,170 was provided by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) to Louisiana State University Health Sciences Center-Shreveport. The grant aims to investigate the mechanisms inducing neural fibroblasts (NFs) derived from peripheral nerves to become part of the carcinoma-associated fibroblast (CAF) population, reprogram lipid storage, and promote neuritic-like processes formation, ultimately stimulating tumor progression. The research seeks to understand the role of the DGAT1-BDNF axis in activating CAFs and generating a nerve and lipid-rich tumor microenvironment, which may contribute to the higher incidence of perineural invasion observed in prostate cancer among African American patients. The project will run from September 2025 to July 2029 and explore potential therapeutic approaches targeting the DGAT1-BDNF axis to suppress lipid reprogramming, block excess neural density, and prevent perineural invasion related to tumor progression.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.6m | 9/12/25 |